Cryo Cell International (CCEL) Q2 2026 earnings summary

Executive summary

• Revenue for the six months ended May 31, 2026 was $15.46M, down 3% year-over-year, mainly due to a decline in new domestic cord blood specimens processed, partially offset by higher recurring storage fees.

• Net income for the six months was $601,694, compared to $638,640 in the prior year period.

• The company is engaged in ongoing arbitration with Duke University over a terminated license agreement, impacting expansion plans.

Financial highlights

• Six-month revenue decreased to $15.46M from $15.90M year-over-year.

• Net income for the six months was $601,694, down from $638,640 year-over-year.

• Gross margin improved as cost of sales declined 13% to $3.33M.

• Operating income for the six months was $1.96M, down from $2.55M year-over-year.

• Diluted EPS for the six months was $0.07, compared to $0.08 in the prior year.

Outlook and guidance

• The company anticipates sufficient liquidity for at least the next 12 months, with future investments in Duke-related activities on hold pending arbitration outcome.

• Expansion into infusion clinics and biopharmaceutical manufacturing is paused.